U.S. Sterility Testing Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

The sterility testing market in the United States is undergoing substantial expansion, reflecting both the rapid development of advanced therapies and tightening regulatory requirements. In 2025, the market was valued at approximately US$ 536.58 million and is expected to reach US$ 1.59 billion by 2035, growing at a CAGR of 11.54% during the forecast period from 2026 to 2035. This growth is primarily driven by the increasing importance of sterility assurance within pharmaceutical and biotechnology manufacturing processes.

One of the most significant drivers behind this expansion is the rising demand for biologics. These therapies are derived from living organisms and require highly controlled manufacturing environments to prevent microbial contamination. As the number of biologic therapies entering development pipelines increases, pharmaceutical companies are strengthening sterility testing frameworks to ensure regulatory compliance and patient safety.

Noteworthy Market Developments

The United States sterility testing market is shaped by a combination of global laboratory service providers and specialized testing technology companies. Large testing networks continue expanding through acquisitions to strengthen their service capabilities and geographic reach.

Eurofins Scientific has emerged as a dominant player, aggressively expanding its laboratory footprint through strategic acquisitions. In the first half of 2024 alone, the company completed 15 acquisitions, significantly enhancing its testing network. Nelson Labs, a subsidiary of Sotera Health, has also maintained a strong position in the market through innovation. In March 2025, the company introduced a Rapid Sterility Testing (RST) service capable of reducing testing turnaround time to six days, highlighting the industry’s focus on faster, more efficient testing solutions.

Core Growth Drivers

The growing complexity of pharmaceutical and biotechnology products is a central driver of the sterility testing market. Modern therapies, particularly biologics, require sophisticated manufacturing processes involving living cells, which increases the risk of contamination during production. This heightened risk makes sterility testing an essential quality assurance step to confirm that pharmaceutical products meet strict safety standards before reaching patients.

Emerging Opportunity Trends

Increasing FDA approvals are significantly boosting sterility testing demand in the United States. As more innovative therapies move through development pipelines and reach commercialization, each production batch must undergo rigorous sterility verification before release. This surge in new drug approvals is increasing the volume of testing required across pharmaceutical manufacturers and contract testing laboratories.

Barriers to Optimization

A shortage of professionals skilled in aseptic techniques and sterility validation remains a key constraint for the industry. Sterility testing requires highly specialized expertise to ensure accurate results and maintain contamination-free laboratory environments. The lack of adequately trained personnel can limit laboratory capacity and slow testing workflows, particularly as demand for sterility testing continues to rise.

Detailed Market Segmentation

Based on test type, membrane filtration dominates the sterility testing market with a share of over 46.33%. This leadership is strongly supported by regulatory mandates such as the United States Pharmacopeia (USP) < 71>, which recommends membrane filtration as the preferred testing method for filterable pharmaceutical products.

Based on product type, sterility testing kits account for over 49.17% of the market. Their widespread adoption reflects the increasing need for reliable, standardized testing procedures within pharmaceutical and biotechnology laboratories.

Based on end users, pharmaceutical companies represent the largest market segment with a share exceeding 44.78%. Their dominance reflects the stringent quality control requirements associated with pharmaceutical manufacturing and regulatory compliance.

Segment Breakdown

By Product

• Kits
• Services
• Instruments

By Test

• Membrane Filtration
• Direct Transfer
• Product Flush

By Application

• Medical Devices
• Pharmaceutical Products
• Other Applications

By End User

• Hospitals & Clinics
• Pharmaceutical Companies
• Research Laboratories
• Others

Leading Market Participants

• Thermo Fisher Scientific Inc.
• Charles River Laboratories International, Inc.
• Sartorius AG
• SGS S.A
• bioMérieux SA
• Eurofins Scientific
• Alcami Corporation
• Pacific BioLabs, Inc.
• Bioquell (Ecolab Solution)
• Merck
• Other Prominent Players